Planta Med 2015; 81(06): 495-506
DOI: 10.1055/s-0035-1545884
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Revealing Medicinal Plants That Are Useful for the Comprehensive Management of Epilepsy and Associated Comorbidities through In Silico Mining of Their Phytochemical Diversity

Rajesh Kumar Goel
1   Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
Dinesh Gawande
1   Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
Alexey Lagunin
2   Orekhovich Institute of Biomedical Chemistry, Moscow, Russia
Puneet Randhawa
1   Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
Awanish Mishra
1   Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
Vladimir Poroikov
2   Orekhovich Institute of Biomedical Chemistry, Moscow, Russia
› Author Affiliations
Further Information

Publication History

received 11 July 2014
revised 24 February 2015

accepted 27 February 2015

Publication Date:
09 April 2015 (online)


In silico techniques in drug discovery may rationalise and speed up the identification of lead molecules from nature. Drug discovery from medicinal plants has mostly been confined to indications in accordance with their ethnical use only. However, the availability of multiple phytoconstituents in medicinal plants suggests that these may be much more useful beyond their traditional uses and in the management of chronic diseases, along with their comorbidities. In this study, the computer programmes PASS and PharmaExpert were used to reveal the medicinal plants useful in the comprehensive management of epilepsy and associated psychiatric disorders based on the pleiotropic effects predicted for their phytoconstituents. In silico analysis revealed that seven of 50 medicinal plants from traditional Indian medicine possessed the desired pleiotropic effect, i.e., anticonvulsant, antidepressant, and nootropic activities. The majority of phytoconstituents from Passiflora incarnata were concurrently predicted to have the desired pleiotropic effects. Therefore, P. incarnata was pharmacologically validated using the pentylenetetrazole kindling mouse model. Behavioural and neurochemical evaluations confirmed the ameliorative role of P. incarnata in epilepsy and the associated depression and memory deficit. The pharmacological findings from this study propose that PASS and PharmaExpert may serve as good tools for the optimisation of the selection of plants based on their phytoconstituents for the treatment of different ailments, even beyond their traditional use.

Supporting Information

  • References

  • 1 Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ 1985; 63: 965-981
  • 2 Benzie IFF, Wachtel-Galor S. Herbal medicine: biomolecular and clinical aspects. 2nd. edition. Boca Raton: CRC Press; 2011: 1-499
  • 3 Hirayama C, Ono H, Meng Y, Shimada T, Daimon T. Flavonoids from the cocoon of Rondotia menciana . Phytochemistry 2013; 94: 108-112
  • 4 Costa EV, Teixeira SD, Marques FA, Duarte MC, Delarmelina C, Pinheiro ML, Trigo JR, Sales Maia BH. Chemical composition and antimicrobial activity of the essential oils of the Amazon Guatteriopsis species. Phytochemistry 2008; 69: 1895-1899
  • 5 Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 2011; 12: 122-132
  • 6 Singh B, Singh D, Goel RK. Dual protective effect of Passiflora incarnata in epilepsy and associated post-ictal depression. J Ethnopharmacol 2012; 139: 273-279
  • 7 Yemadje LP, Houinato D, Quet F, Druet-Cabanac M, Preux PM. Understanding the differences in prevalence of epilepsy in tropical regions. Epilepsia 2011; 52: 1376-1381
  • 8 Rudzinski LA, Meador KJ. Epilepsy and neuropsychological comorbidities. Continuum (Minneap Minn) 2013; 19: 682-696
  • 9 Hommet C, Mondon K, Camus V, De Toffol B, Constans T. Epilepsy and dementia in the elderly. Dement Geriatr Cogn Disord 2008; 25: 293-300
  • 10 Jobe PC, Browning RA. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 2005; 7: 602-619
  • 11 Cotterman-Hart S. Depression in epilepsy: why arenʼt we treating?. Epilepsy Behav 2010; 19: 419-421
  • 12 Griffith HR, Martin R, Andrews S, LeBron Paige A, Ware J, Faught E, Welty T. The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. Epilepsy Behav 2008; 13: 376-380
  • 13 Dalkara S, Karakurt A. Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders. Curr Top Med Chem 2012; 12: 1033-1071
  • 14 Choudhary KM, Mishra A, Poroikov VV, Goel RK. Ameliorative effect of Curcumin on seizure severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice. Eur J Pharmacol 2013; 704: 33-40
  • 15 Singh D, Gawande DY, Singh T, Poroikov V, Goel RK. Revealing pharmacodynamics of medicinal plants using in silico approach: a case study with wet lab validation. Comput Biol Med 2014; 47: 1-6
  • 16 Computer-aided study of hidden potential in TIM. Available at Accessed July 15, 2014.
  • 17 Dictionary of Natural Products. Available at Accessed July 15, 2014.
  • 18 Gholipour T, Ghasemi M, Riazi K, Ghaffarpour M, Dehpour AR. Seizure susceptibility alteration through 5-HT(3) receptor: modulation by nitric oxide. Seizure 2010; 19: 17-22
  • 19 De Sarro G, De Sarro A, Federico F, Meldrum BS. Anticonvulsant properties of some calcium antagonists on sound-induced seizures in genetically epilepsy prone rats. Gen Pharmacol 1990; 21: 769-778
  • 20 Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996; 67: 2079-2086
  • 21 Yang Z, Liu X, Yin Y, Sun S, Deng X. Involvement of 5-HT7 receptors in the pathogenesis of temporal lobe epilepsy. Eur J Pharmacol 2012; 685: 52-58
  • 22 Palmer GC. Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum. Exp Neurol 1979; 63: 322-335
  • 23 Wang QP, Jammoul F, Duboc A, Gong J, Simonutti M, Dubus E, Craft CM, Ye W, Sahel JA, Picaud S. Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 2008; 27: 2177-2187
  • 24 Eldefrawi AT, Eldefrawi ME. Receptors for gamma-aminobutyric acid and voltage-dependent chloride channels as targets for drugs and toxicants. FASEB J 1987; 1: 262-271
  • 25 Haefely W, Facklam M, Schoch P, Martin JR, Bonetti EP, Moreau JL, Jenck F, Richards JG. Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders. Adv Biochem Psychopharmacol 1992; 47: 379-394
  • 26 Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001; 42: 8-12
  • 27 Zangen A, Overstreet DH, Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. J Neurochem 1997; 69: 2477-2483
  • 28 Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, Bondy B, Parsons C, Gilling K, Zieglgänsberger W, Holsboer F, Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry 2003; 8: 994-1007
  • 29 Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors. A review of antidepressant effectiveness. Arch Gen Psychiatry 1979; 36: 749-760
  • 30 Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?. J Psychiatry Neurosci 2003; 28: 409-414
  • 31 Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, Miller K, Atack J, Lovenberg TW, Dugovic C. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007; 321: 690-698
  • 32 Wang J, Mack AL, Coop A, Matsumoto RR. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol 2007; 17: 708-716
  • 33 Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 2002; 303: 1227-1237
  • 34 Jain S, Agarwal NB, Mediratta PK, Sharma KK. Evaluation of anticonvulsant and nootropic effect of ondansetron in mice. Hum Exp Toxicol 2012; 31: 905-912
  • 35 Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, OʼDonnell JM. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000; 23: 198-204
  • 36 Yoshii M, Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108–15 cells. Brain Res 1994; 642: 123-131
  • 37 Cahill L, Alkire MT. Epinephrine enhancement of human memory consolidation: interaction with arousal at encoding. Neurobiol Learn Mem 2003; 79: 194-198
  • 38 Ghelardini C, Galeotti N, Bartolini A, Furukawa S, Nitta A, Manetti D, Gualtieri F. Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9. Jpn J Pharmacol 1998; 78: 245-251
  • 39 Chetkovich DM, Sweatt JD. NMDA receptor activation increases cyclic AMP in area CA1 of the hippocampus via calcium/calmodulin stimulation of adenylyl cyclase. J Neurochem 1993; 61: 1933-1942
  • 40 Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007; 59: 360-417
  • 41 Bhatnagar S, Nowak N, Babich L, Bok L. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res 2004; 153: 527-535
  • 42 Ramamoorthy R, Radhakrishnan M, Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: aninvestigation in behaviour-based rodent models. Behav Pharmacol 2008; 19: 29-40
  • 43 Redrobe JP, Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997; 325: 129-135
  • 44 Kalichman MW. Neurochemical correlates of the kindling model of epilepsy. Neurosci Biobehav Rev 1982; 6: 165-181
  • 45 Rocha L, Briones M, Ackermann RF, Anton B, Maidment NT, Evans CJ, Engel jr. J. Pentylenetetrazol-induced kindling: early involvement of excitatory and inhibitory systems. Epilepsy Res 1996; 26: 105-113
  • 46 Sejima H, Ito M, Kishi K, Tsuda H, Shiraishi H. Regional excitatory and inhibitory amino acid concentrations in pentylenetetrazol kindling and kindled rat brain. Brain Dev 1997; 19: 171-175
  • 47 Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997; 48: 649-684
  • 48 Szyndler J, Maciejak P, Turzyńska D, Sobolewska A, Bidziński A, Płaźnik A. Time course of changes in the concentrations of monoamines in the brain structures of pentylenetetrazole-kindled rats. J Neural Transm 2010; 117: 707-718
  • 49 Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999; 13: 317-356
  • 50 Matsumoto M, Yoshioka M, Togashi H, Tochihara M, Ikeda T, Saito H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 1995; 272: 1044-1051
  • 51 Reiser G. Mechanism of stimulation of cyclic-GMP level in a neuronal cell line mediated by serotonin (5-HT3) receptors. Involvement of nitric oxide, arachidonic-acid metabolism and cytosolic Ca2+ . Eur J Biochem 1990; 189: 547-552
  • 52 Zhao RR, Xu XC, Xu F, Zhang WL, Zhang WL, Liu LM, Wang WP. Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. Biochem Biophys Res Commun 2014; 448: 414-417
  • 53 Mishra A, Goel RK. Age dependent learning and memory deficit in Pentylenetetrazol kindled mice. Eur J Pharmacol 2012; 674: 315-320
  • 54 Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res 2011; 133: 471-478
  • 55 Han D, Yamada K, Senzaki K, Xiong H, Nawa H, Nabeshima T. Involvement of nitric oxide in pentylenetetrazole-induced kindling in rats. J Neurochem 2000; 74: 792-798
  • 56 Szyndler J, Rok P, Maciejak P, Walkowiak J, Członkowska AI, Sienkiewicz-Jarosz H, Wisłowska A, Zienowicz M, Lehner M, Bidziński A, Kostowski W, Plaznik A. Effects of pentylenetetrazol-induced kindling of seizures on rat emotional behavior and brain monoaminergic systems. Pharmacol Biochem Behav 2002; 73: 851-861
  • 57 Filimonov D, Poroikov V. Probabilistic approaches in activity prediction. In: Varnek A, Tropsha A, editors Chemoinformatics approaches to virtual screening. Cambridge: Wiley; 2008: 182-216
  • 58 Poroikov VV, Filimonov DA, Borodina YV, Lagunin AA, Kos A. Robustness of biological activity spectra predicting by computer program PASS for noncongeneric sets of chemical compounds. J Chem Inf Comput Sci 2000; 40: 1349-1355
  • 59 Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, Poroikov VV. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Comp 2014; 50: 444-457
  • 60 Poroikov V, Lagunin A, Filimonov D. PharmaExpert: diseases, targets and ligands-three in one. In: Sener EA, Yalcin I, editors QSAR and molecular modelling in rational design of bioactive molecules. Ankara: CADDD Society; 2005: 514-515
  • 61 Kartal M, Altun ML, Kurucu S. HPLC method for the analysis of harmol, harmalol, harmine and harmaline in the seeds of Peganum harmala L. J Pharm Biomed Anal 2003; 31: 263-269
  • 62 Singh D, Mishra A, Goel RK. Effect of saponin fraction from Ficus religiosa on memory deficit, and behavioral and biochemical impairments in Pentylenetetrazole kindled mice. Epilepsy Behav 2013; 27: 206-211
  • 63 Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367-370
  • 64 Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn 1977; 229: 327-336
  • 65 Mishra A, Goel RK. Psychoneurochemical investigations to reveal neurobiology of memory deficit in epilepsy. Neurochem Res 2013; 38: 2503-2515